M1 Ltd. Stock
Price
Target price
-
-
-
-
-
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of M1 Ltd. in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
B****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of M1 Ltd. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| M1 Ltd. | - | - | - | - | - | - | - |
| Spok Holdings Inc. | -1.080% | 2.222% | -0.541% | -34.613% | -16.211% | -20.000% | -1.604% |
| SmarTone Telecommunications Holdings Ltd | -1.820% | 2.857% | 0.000% | 13.445% | 9.312% | -1.818% | 6.931% |
| Apt Satellite Hldgs | - | 0.000% | 0.000% | -3.571% | -24.400% | -30.000% | -26.172% |
News
Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential
Key Points
- Interested in Contineum Therapeutics, Inc.? Here are five stocks we like better.
- Contineum remains focused on PIPE-791 for idiopathic pulmonary fibrosis (IPF), saying the drug’s
IRSA Inversiones Y Representaciones Q3 Earnings Call Highlights
IRSA Inversiones Y Representaciones (NYSE:IRS) reported a sharply higher net result for the first nine months of fiscal 2026, supported by stronger performance across its rental businesses and